First human tests begin for promising new MS treatment
NCT ID NCT05704361
Summary
This early-stage study aims to check the safety and side effects of a new drug called RO7121932 in people with multiple sclerosis (MS). Researchers will give the drug to 129 participants, first through an IV and then as an injection under the skin, while carefully monitoring for any problems. The main goal is to see how well the drug is tolerated and how the body handles it, which is a necessary first step before testing if it can help control MS.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ARENSIA Exploratory Medicine Phase I, PMSI Republican Clinical Hospital
COMPLETEDChisinau, MD-2025, Moldova
-
ARENSIA Exploratory Medicine SRL - Bucharest (Monza Medical Center)
RECRUITINGBucharest, 011658, Romania
-
ARENSIA Exploratory Medicine, County Emergency Hospital
RECRUITINGCluj-Napoca, 40006, Romania
-
Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião
RECRUITINGSanta Maria da Feira, 4520-211, Portugal
-
Cliniques Universitaires St-Luc
RECRUITINGBrussels, 1200, Belgium
-
Fond. Istituto Neurologico C.Besta
RECRUITINGMilan, Lombardy, 20133, Italy
-
Hadassah University Hospital - Ein Kerem
RECRUITINGJerusalem, 9112001, Israel
-
Hospital Santo Antonio dos Capuchos
RECRUITINGLisbon, 1169-050, Portugal
-
Hospital Universitari Vall dHebron (CEMCAT)
RECRUITINGBarcelona, 08035, Spain
-
Hospital de Braga
RECRUITINGBraga, 4710-243, Portugal
-
IRCCS Ospedale San Raffaele
RECRUITINGMilan, Lombardy, 20132, Italy
-
Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
WITHDRAWNWarsaw, 02-957, Poland
-
Klinikum rechts der Isar der TU Muenchen
COMPLETEDMünchen, 81675, Germany
-
MedPolonia
RECRUITINGPoznan, 60-693, Poland
-
Montreal Neurological Institute and Hospital
RECRUITINGMontreal, Quebec, H3A 2B4, Canada
-
Osrodek Badan Klinicznych Euromedis
RECRUITINGSzczecin, 70-111, Poland
-
Regionalny Szpital Specjalistyczny im. W. Bieganskiego
COMPLETEDGrudzi?dz, 86-300, Poland
-
SPSK nr 1
RECRUITINGZabrze, 41-800, Poland
-
Stanford University Medical Center
COMPLETEDStanford, California, 94305, United States
-
Tel Aviv Sourasky Medical Center
WITHDRAWNTel Aviv, 6423906, Israel
-
UC Health, LLC.
WITHDRAWNCincinnati, Ohio, 45267, United States
-
UZ Gent
RECRUITINGGhent, 9000, Belgium
-
University Clinical Center of Serbia
RECRUITINGBelgrade, 11000, Serbia
-
University of Massachusetts Medical School
WITHDRAWNWorcester, Massachusetts, 01655, United States
-
University of South Florida
WITHDRAWNTampa, Florida, 33612, United States
-
Universitätsklinikum "Carl Gustav Carus"
COMPLETEDDresden, 01307, Germany
-
Universitätsklinikum Münster Klinik u. Poliklinik f. Neurologie
RECRUITINGMünster, 48149, Germany
-
Universitätsklinikum Tübingen, Zentrum für Neurologie
RECRUITINGTübingen, 72076, Germany
-
Universitätsklinikum Ulm
RECRUITINGUlm, 89081, Germany
-
Universitätsmedizin Göttingen Georg-August-Universität
COMPLETEDGöttingen, 37075, Germany
-
Uniwersyteckie Centrum Kliniczne
WITHDRAWNGda?sk, 80-214, Poland
-
Yale University Multiple Sclerosis Center
COMPLETEDNew Haven, Connecticut, 06473, United States
Conditions
Explore the condition pages connected to this study.